Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer
The investment in land is Rs. 19.85 crore
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Subscribe To Our Newsletter & Stay Updated
